Tissue plasminogen activator (tPA) is used in fewer than 4% of patients after ischemic stroke because of its narrow therapeutic time window. We tested whether pyrrolidine dithiocarbamate (PDTC), a drug with multiple mechanisms to provide neuroprotection, can be used to extend the therapeutic time window of tPA. Three-month-old male Sprague-Dawley rats were subjected to embolic stroke in the area supplied by the right middle cerebral artery. tPA at 10 mg/kg was given intravenously 4 h after the onset of stroke. PDTC at 50 mg/kg was given via gastric gavage at 30 min or 4 h after the onset of stroke.
outweigh its benefits if it is used at a time point that is more than 3 h after the onset of brain ischemia (Adams et al., 2007) , although this therapeutic time window may be extended to 4.5 h in selective cases (Del Zoppo, Saver, Jauch, & Adams, 2009 ). The major side effects of tPA include hemorrhagic transformation (HT), an effect that may be mediated by activation of matrix metalloprotease (MMP; Montaner et al., 2003) , and direct neurovascular toxicity (Liu et al., 2004; NINDS, 1997; Wang et al., 2012; Wang et al., 1998) . Due to this narrow therapeutic time window, intravenous tPA is currently used only in fewer than 4% of patients with ischemic stroke (Kleindorfer, Lindsell, Brass, Koroshetz, & Broderick, 2008) . Methods to extend the therapeutic time window of tPA are highly sought to improve the outcome of patients with ischemic stroke.
Pyrrolidine dithiocarbamate (PDTC) is a small molecule with antioxidant and anti-inflammatory properties (Liu, Ye, Malik, 1999) . PDTC has been shown to activate Akt, a protein that is considered to be prosurvival. PDTC can reduce focal brain ischemic injury in young adult rats (Nurmi et al., 2004a; Nurmi et al., 2004b) . This protective effect occurs even if the application of PDTC is at 6 h after the onset of transient focal brain ischemia in those rats (Nurmi et al., 2004b) . Our recent study showed that oral PDTC started at 10 min after brain ischemia improved neurological outcome assessed at 1 or 2 months later in young adult rats (Li, Sheng, Feng, & Zuo, 2012) . PDTC also reduced brain injury after ischemia and hypoxia in neonatal rats (Nurmi et al., 2006; Wang, Zhao, Peng, & Zuo, 2013) . Thus, we hypothesize that PDTC can be used to extend the therapeutic time window of tPA. To test this hypothesis, rats were subjected to embolic stroke and then treated with tPA in the presence or absence of PDTC. Their neurological outcome was assessed. 
| M E TH ODS AN D M A TER I A LS

| Animal groups
Male Sprague-Dawley rats (RRID: RGD_5508379), weighing from 280 g to 310 g (Charles River Laboratories Inc.), were randomly assigned to the following groups: 1) embolic stroke, 2) embolic stroke plus tPA treatment, 3) embolic stroke plus PDTC treatment at 30 min after the onset of stroke, 4) embolic stroke plus PDTC treatment at 30 min after the onset of stroke plus tPA treatment, 5) embolic stroke plus PDTC treatment at 4 h after the onset of stroke, and 6) embolic stroke plus PDTC treatment at 4 h after the onset of stroke plus tPA treatment. Each group had 8 rats. tPA was given intravenously at 4 h after the onset of stroke. PDTC was given via gastric gavage. Normal saline (NS) at equal volume was applied intravenously or via gastric gavage at the corresponding times in animals that did not receive PDTC or tPA. These rats were used to evaluate the neurological outcome at 2 days after the stroke.
A second cohort of rats were randomly assigned to the following groups: 1) sham, 2) embolic stroke, 3) embolic stroke plus tPA treatment, 4) embolic stroke plus PDTC treatment at 30 min after the onset of stroke, and 5) embolic stroke plus PDTC treatment at 30 min after the onset of stroke plus tPA treatment. Each group also had 8 rats. tPA was also given intravenously at 4 h after the onset of stroke. These rats were used to harvest the right frontal cortex area 1 (Fr1), an ischemic penumbral region (Li et al., 2013; Li & Zuo, 2011a; Li & Zuo, 2011b) , at 2 days after the stroke.
| Preparation of the blood embolus
The method used to prepare a white embolus was modified from a previous study (Overgaard et al., 1992) . Briefly, blood was withdrawn from a femoral artery of a donor rat under isoflurane anesthesia and then filled into a 20 cm long PE-50 tube. The blood was allowed to clot in the tube for 2 h at room temperature and then kept for 22 h at 4 8C.
A five-centimeter long PE-50 tube containing the clot was cut and attached at both ends to a 20 cm long PE-10 tube that was connected to a syringe via a 30-gauge needle. The PE-10 tube and syringes were filled with saline and the clot was shifted by alternating movement from one syringe to the other for 5 min. A single clot of 25 mm was cut and transferred to a PE-0402 tube (Anilab Software & Instruments Co., Ltd.) filled with saline. The PE-0402 tube had a 0.38 mm outer diameter and 0.2 mm inner diameter.
| Animal model
The embolic stroke model was modified from a previous study (Zhang et al., 1997) . Rats were anesthetized with 2% isoflurane. Rectal temperature was maintained at 37 8C with a feedback regulated heating pad.
The right common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA) were isolated under a microscope via a midline incision. A 6-0 silk suture was loosely tied at the origin of the ECA. Another suture was used to ligate the distal end of the ECA. The Significance Stroke is a leading cause of mortality and morbidity. About 4% of patients benefit from using tissue plasminogen activator (tPA) that can open the blocked blood vessels. Most patients arrive at the hospital too late (i.e., not within the therapeutic time window of tPA). We showed that pyrrolidine dithiocarbamate (PDTC) improved neurological outcome after a delayed use of tPA in rats with stroke. PDTC reduced bleeding in the brain of animals treated with tPA. Bleeding is a side effect of tPA. Thus, our study identified a small molecule that potentially can be used with tPA to improve the outcome of patients with stroke.
right CCA and ICA were temporarily clamped using a curved microvascular clip. The PE-0402 tube containing a 25 mm long clot was attached to a 100 ml Hamilton syringe and introduced into the ECA lumen through a small puncture. The suture around the origin of the ECA was tightened around the intraluminal catheter to prevent bleeding and the microvascular clip was removed. About 20 mm length of catheter was gently advanced from the ECA into the lumen of the ICA.
The clot along with 50 ml of saline was injected into the ICA over 10 s.
The catheter was removed from the right ECA 5 min after the injection.
The right ECA was ligated. The duration of the entire surgical procedure was within 30 min. Heparin was not administered to any animals.
| Drug application
tPA (Genentech) solution was prepared by diluting with sterile water to 3 mg/ml and kept at -80 8C. tPA at 10 mg/kg was injected intravenously through a tail vein as reported before (Ding et al., 2005) . PDTC solution was prepared by dissolving PDTC powder in NS to 10 mg/ml just before use. PDTC at 50 mg/kg was administered to rats via gastric gavage .
| Evaluation of motor coordination, neurological deficit scores, infarct volumes, and hemorrhagic volumes
Motor coordination was evaluated by using an accelerating rotarod as we described before (Li et al., 2013 ). Each rat was tested three times.
The latency and speed of rats falling off the rotarod were recorded.
The speed-latency index (latency in seconds x speed in rpm) of each of the three tests was calculated and averaged for reporting. Animals were tested before the embolic stroke and immediately before they were sacrificed for assessment of brain infarct volume. The ratio of speed-latency index after the stroke/speed-latency index before the stroke was used to reflect the motor coordination.
Neurological deficit scores were evaluated based on an eight-point scale by a person who was blind to the group assignment as we described before (Li et al., 2013; Li & Zuo, 2011b) .
Infarct volumes were measured after staining of the 2-mm thick brain slices with 2% 2,3,5-triphenyltetrazolium chloride as we described before (Li et al., 2013; Li & Zuo, 2011b) . The percentage of brain infarct volume in the ipsilateral hemisphere volume was calculated to account for cerebral edema and differential shrinkage from brain ischemia and tissue processing and to correct for individual differences in brain volumes (Li & Zuo, 2011a) . The hemorrhagic volumes were measured in the same way as measuring infarct volumes before the slices were stained by 2,3,5-triphenyltetrazolium chloride (Deng et al., 2014 ).
| Brain tissue harvesting
Rats with or without brain ischemia were deeply anesthetized by isoflurane and transcardially perfused with NS at 2 days after the embolic stroke. The right Fr1 between bregma 1 2 and bregma 0 mm and between 1 to 3 mm from the midline was harvested as we described before (Li et al., 2013; Li & Zuo, 2011a; Li & Zuo, 2011b) for evaluation of oxidative stress, MMP activity and ELISA of cytokines.
| ELISA Assay of cytokines in the brain tissues
IL-1b, IL-6, and TNF-a levels in the Fr1 were determined with Quantikine ELISA kits (R&D Systems) according to the manufacturer's instructions as we described before (Cao, Li, Lin, & Zuo, 2012; Lin & Zuo, 2011) . The quantity of IL-1b, TNF-a, and IL-6 in each brain sample was normalized to its protein contents.
| Measurement of malondialdehyde (MDA) level, superoxide dismutase (SOD) activity and 4-hydroxy-2-nonenal (HNE) content
The levels of MDA, SOD activity and HNE in the brain tissues were assessed according to the manufacture's instructions using the OxiSe- 
| MMP zymography
The MMP activity was measured by gelatin zymography as we reported before (Ding et al., 2005) . Forty-five micrograms of cytoplas- 
| RE S U L TS
No rats had an episode of hypoxia during the surgery to create the embolic stroke. No rats died during the perioperative period (within one hour after the surgery). 3.2 | PDTC gave at an early time point reduced inflammatory and oxidative response in the ischemic brain tissues
There was a significant increase in the expression of TNF-a, IL-1b, and IL-6, proinflammatory cytokines, in the ischemic penumbral Fr1. This increase in the presence or absence of tPA was attenuated by PDTC given at 30 min after the onset of stroke (from 208 6 103 pg/mg protein to 52 6 17 pg/mg protein for IL-1b in the absence of tPA, n 5 8, 
| D I SCUSSION S
Our results clearly showed that PDTC applied 30 min after the onset of brain ischemia induced neuroprotection. More importantly, application of PDTC at this time point improved the outcome of rats treated with tPA given 4 h after the onset of brain ischemia, suggesting that PDTC can be used to extend the therapeutic time window of tPA.
Reopening the occluded blood vessels as soon as possible after the onset of ischemic stroke is obviously an effective intervention (Berkhemer et al., 2015; Goyal et al., 2015) . Use of tPA for this purpose within 3 h after the onset of stroke is considered beneficial (Adams et al., 2007) . Multiple factors may contribute to the loss of benefits with the delayed use of tPA. First, tPA causes direct neurovascular injury and HT. tPA knockout mice have better neurological outcome after brain ischemia. tPA also induces apoptosis to endothelial cells and neurons (Liu et al., 2004; NINDS, 1997; Wang et al., 2012; Wang et al., 1998) . Second, brain tissues distal to the occluded artery may be severely injured or suffer from irreversible injury when tPA is used at a delayed time point. Third, the reperfusion after tPA use can cause significant reperfusion injury (Lipton, 1999) . The harmful effects caused by these factors outweigh the beneficial effects induced by blood reflowing to the ischemic tissues with a delayed use of tPA. In our study, rats treated with tPA at 4 h after the onset of embolic stroke had a degree of infarct brain volume, brain edema and neurological deficit similar to rats with embolic stroke alone. However, the hemorrhagic volumes in rats treated with tPA was increased compared to rats with embolic stroke alone. These results suggest that tPA use at a delayed time point does not improve neurological outcome but increases hemorrhagic volume. It is not clear whether the failure to improve neurological outcome is due to the failure to save any cells by blood reflowing to the ischemic area or the count balance between the beneficial effects of blood reflowing and the detrimental effects of tPA, reperfusion and increased hemorrhage. However, application of PDTC at 30 min after the onset of stroke improved neurological outcome and attenuated hemorrhagic volume increase caused by tPA, strongly suggesting its neuroprotective effects in the presence of tPA.
We thought to use an agent that has multiple mechanisms to provide neuroprotection for extending the therapeutic time window of tPA because of the complex etiology of ischemia-reperfusion injury
The effects of tPA and PDTC on neurological function. Rats were subjected to an embolic stroke. They received intravenous tPA at 4 h after the onset of stroke or PDTC via gastric gavage at 30 min or 4 h after the onset of stroke. Rats were evaluated 2 days after the stroke. (a) neurological deficit scores. (b) performance in rotarod. Results are in box plot. Inside boxes: 25-75% interval including the median of the data (n 5 8). *p < 0.050 compared with ischemia alone group. #p < 0.050 compared with ischemia plus tPA group (Lipton, 1999) and tPA-induced damage (Liu et al., 2004; NINDS, 1997; Wang et al., 2012; Wang et al., 1998) . PDTC is neuroprotective in many brain ischemia models Nurmi et al., 2006; Nurmi et al., 2004a; Nurmi et al., 2004b; Wang et al., 2013) and has multiple targets for neuroprotection. First, PDTC is an anti-oxidant that scavenges free radicals (Hayakawa et al., 2003) . Second, PDTC is an anti-inflammatory agent. It inhibits the nuclear factor jB (NF-jB; Liu et al., 1999; Schreck et al., 1992) , a transcription factor that is necessary for the expression of proinflammatory mediators. PDTC reduces ischemia-reperfusion-induced IL-1b and TNFa production in the brain FIG URE 3 The effects of tPA and PDTC on hemorrhagic volume and MMP2 activity.Rats were subjected to an embolic stroke. They received intravenous tPA at 4 h after the onset of stroke or PDTC via gastric gavage at 30 min or 4 h after the onset of stroke. Rats were evaluated 2 days after the stroke. of young adult rat (Nurmi et al., 2004b) . Third, it has been shown that PDTC can activate Akt, which then activates downstream proteins to support cell survival (Nurmi et al., 2006) . Apart from these three mechanisms, we showed that PDTC reduced ischemia-reperfusion-induced amyloid b peptide (Ab) production . Ab can cause oxidative injury to cells (Agostinho, Cunha, & Oliveira, 2010 et al., 2004a; Nurmi et al., 2004b; Wang et al., 2013) , our results showed that PDTC given 30 min after the embolic stroke improved neurological outcome no matter whether the rats were treated with tPA at 4 h after the onset of stroke. PDTC also reduced the increase of hemorrhagic volume in rats treated with tPA. As expected, PDTC reduced proinflammatory cytokines, such as TNF-a, IL-1b, and IL-6 and oxidative stress as reflected by the decreased 4-HNE, a lipid oxidative stress index (Li & Zuo, 2011a) , and MDA, a highly reactive compound, FIG URE 4 The effects of tPA and PDTC on proinflammatory cytokine expression.Rats were subjected to an embolic stroke. They received intravenous tPA at 4 h after the onset of stroke or PDTC via gastric gavage at 30 min after the onset of stroke. The right frontal cortex area 1 was evaluated 2 days after the stroke. in the ischemic penumbral region. PDTC also preserved SOD activity in the ischemic penumbral region. SOD is an important antioxidative enzyme (McCord & Fridovich, 1988) . The preservation of SOD activity may facilitate the reduction of oxidative stress in the ischemic tissues.
There are at least two mechanisms for the hemorrhage to occur after ischemic stroke: direct neurovascular injury and activation of MMPs. Use of tPA can enhance hemorrhage because tPA can cause direct neurovascular injury (Liu et al., 2004; NINDS, 1997; Wang et al., 2012; Wang et al., 1998) and enhance MMP activation (Montaner et al., 2003) . In addition, blood reflowing to the ischemic area may facilitate the formation of hemorrhage. Consistent with these ideas, tPA use at 4 h after the onset of embolic stroke increased the hemorrhagic volume and MMP2 activity and these effects were attenuated by PDTC. These results suggest a role of MMP2 in the HT after tPA treatment. Previous studies have shown a role of MMP9 in ischemic brain injury and the brain damage after tPA treatment (Montaner et al., 2003; Turner & Sharp, 2016) . It is unclear why we could not detect a band corresponding to MMP9 in our study.
A previous study showed that PDTC use started at 6 h after the onset of ischemic stroke induced by an intravascular suture was neuroprotective in rats (Nurmi et al., 2004b) . PDTC was given every 12 h and brain ischemia was for 90 min in that study. In our study, PDTC given at 4 h after the onset of embolic stroke was not protective. Application of PDTC at this time did not provide any benefits to the rats treated with tPA at 4 h after the onset of the stroke. We gave only one dose of PDTC. Multiple differences in the experimental design between our study and the previous study (Nurmi et al., 2004b ) may explain the discrepancy in findings of PDTC effects when it is applied in a delayed phase. Giving multiple doses may be useful but our previous study showed that one dose of PDTC is as protective as multiple doses of PDTC (Wang et al., 2013) . Also, one dose of PDTC given 30 min after the onset of stroke improved neurological outcome in the current study.
As discussed above, tPA can induce neurovascular injury (Liu et al., 2004; NINDS, 1997; Wang et al., 2012; Wang et al., 1998) . It has been shown that tPA can cause remote parenchymal hemorrhage, especially in patients with microbleeds (Charidimou et al., 2015; Kimura et al., 2013; Prats-Sanchez et al., 2016) . Interestingly, recombinant activated protein C has been shown to provide neuroprotective effects and reduce parenchymal hemorrhage by blocking the damaging pathways induced by tPA (Cheng et al., 2006; Liu et al., 2004; Wang et al., 2012) .
The safety and effectiveness of intravenous recombinant activated protein C in patients that received tPA are tested in a phase 2 clinical trial (NCT02222714; Amar et al., 2015) . Of note, our current study showed that PDTC via gastric gavage, similar to intravenous activated protein C, reduced cerebral hemorrhage volume caused by tPA.
To reduce the interference of anesthesia/anesthetics in the neurological outcome after a stroke, we did not monitor cerebral blood flow to determine the number of rats that had recanalization to the ischemic brain region after tPA application. A previous study using a similar embolic stroke model showed that up to 50% of rats had recanalization after 10 mg/kg tPA compared with 20% of rats with recanalization in the control group at 24 h after the embolic stroke (Ding et al., 2005) .
Of note, the effects of PDTC on cerebral blood flow to the ischemic brain region are not known. However, PDTC via its inhibition on inflammation can attenuate cerebral vasospasm caused by subarachnoid hemorrhage in rabbits (Zhou et al., 2007) . Thus, it is conceivable that PDTC may improve blood flow to the ischemic brain regions, which may be a mechanism for its neuroprotection.
Our findings may have significant implications. PDTC was given via gastric gavage. This route of application can be achieved in humans by mouth, which is very convenient. Patients who cannot swallow may receive intranasal spray, as this method of application is neuroprotective in our previous study (Wang et al., 2013) . In addition, PDTC is a safe drug (Chabicovsky et al., 2010) . It is our vision that patients can take PDTC by mouth or via intranasal spray at home soon after the onset of stroke symptoms if the neuroprotective effects of PDTC are confirmed in humans. Patients can then go to the hospital to have further treatment, including tPA therapy. However, PDTC can cause sedation, central nervous excitation, gastrointestinal lesions, and kidney injury in rodents in a pre-clinical safety evaluation study (Chabicovsky et al., 2010) . Nevertheless, the doses to induce these toxic effects were much higher than the dose used in this current study. The intravenous maximum tolerance dose was defined at 100 mg/kg in rats and the oral median lethal dose was > 2000 mg/kg in male rats. There was no significant kidney and liver injury if PDTC dose was < 100 mg/kg via intranasal application once a day for 28 days in rats (Chabicovsky et al., 2010 ). We did not observe side effects after brain ischemia in rats that were treated with oral PDTC at 50 mg/kg once a day for 2 months . Intranasal application of PDTC at 100 mg/kg once a day for 3 days provided neuroprotection without noticeable side effects in neonatal rats (Wang et al., 2013) . Thus, current studies suggest the safety of using PDTC to provide neuroprotection. However, additional pre-clinical studies are needed to understand the safety profile of PDTC to determine its translational potential for providing neuroprotection.
Our study has limitation. We used male rats only in this initial study to avoid the interference of sex difference in the results. Future pre-clinical studies using animals of both sexes will determine whether there is any sex difference in the neuroprotective effects of PDTC.
In summary, our results suggest that PDTC is neuroprotective in embolic stroke. PDTC applied early after the onset of embolic stroke can extend the therapeutic time window of tPA. These neuroprotective effects may be mediated by its anti-inflammatory and anti-oxidative properties.
